Xoma/Ingene merger
Executive Summary
There is "absolutely no reason whatsoever that [Ingene's previous R&D agreement with NeoRx] will create any complication" in the proposed merger with Xoma, an Ingene spokesperson said in response to a story on the merger in the Aug. 14 issue of "The Pink Sheet" (T&G-1). "There is no expectation that any of Ingene's previous arrangements will cause any difficulty with the merger," Xoma said. "The Pink Sheet" had stated that Ingene's arrangement with NeoRx "complicates" the merger. According to Ingene, the NeoRx deal announced in April 1988 gives NeoRx "exclusive worldwide rights to products which contain the chimeric antibodies developed from NeoRx's mouse monoclonals".